Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Hidehito Horinouchi on X: S1801: Neo- vs. adjuvant pembrolizumab for stage III-IV melanoma by @DrSapnaPatel. Striking EFS benefits by neoadjuvant! Simple but highly important clinical question. Expect that it is not limited

Neoadjuvant pembrolizumab administered before surgery improves outcomes of melanoma patients - ecancer

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

Adjuvant Nivolumab or Ipilimumab + Nivolumab for Melanoma Determined by Pathological Response to a Single Dose of Neoadjuvant Nivolumab

A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma

The new era of adjuvant therapies for melanoma

Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial, BMC Cancer

Is earlier better for melanoma checkpoint blockade?

ESMO 2023: Current Peri-Operative Trial Designs and Endpoints: What Do They Mean?

Ongoing immunotherapy trials in neoadjuvant and adjuvant settings and

Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma